Promoter holding
64.27%
LL
Laurus Labs Limited - Due diligence report
A 360° intelligence report on Lauruslabs: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lauruslabs — 360° Intelligence Report
Generated from MCA filings & public records85/100
Trust Score
Low Risk
Lauruslabs is assessed as Low Risk with a Trust Score of 85/100. Lauruslabs is an active public limited indian non-government company incorporated in 2005, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Laurus Labs Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA).
Charges position: 3 open (2,062.31 cr) · 34 satisfied (3,804.21 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Sbicap Trustee Company Limited | 1 | 48.0 cr |
| State Bank Of India | 2 | 48.0 cr |
| Others | 6 | 48.0 cr |
| Hdfc Bank Limited | 4 | 48.0 cr |
| The Hongkong And Shanghai Banking Corporation Limited | 5 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 86/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 5 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| VENKATESWAR REDDY GOGIREDDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH KOSHY CHANDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHAVA SATYANARAYANA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA RAVI KUMAR VANTARAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA RAVI KUMAR VANTARAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GOGIREDDY VENKATESWAR REDDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUNA RAJENDRA BHINGE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMESH SUBRAHMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHAVA SATYANARAYANA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA LAKSHMANA RAO CHUNDURU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SOUMYA CHAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAVINDRANATH KANCHERLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SEKAR KARNAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KRISHNA CHAITANYA CHAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Venkateswar Reddy Gogireddy | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Satyanarayana Chava | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 16 directors on the board.
- CHAVA SATYANARAYANA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 3 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
4
Group entities
6
Capital events
23 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Laurus Generics Gmbh | Subsidiary Company | 74.00% |
| Laurus Generics Inc | Subsidiary Company | 74.00% |
| Laurus Generics Sa (pty) Ltd | Subsidiary Company | 74.00% |
| Laurus Holdings Limited | Subsidiary Company | 74.00% |
| Laurus Synthesis Private Limited | Subsidiary Company | 74.00% |
| Sriam Labs Private Limited | Subsidiary Company | 74.00% |
| Laurus Specialty Chemicals Private Limited | Subsidiary Company | 74.00% |
| Laurus Bio Private Limited | Subsidiary Company | 74.00% |
| Immunoadoptive Cell Therapy Private Limited | Associate Company | 74.00% |
| Ethan Energy India Private Limited | Associate Company | 74.00% |
Key managerial personnel: CHAVA SATYANARAYANA (CEO) · VENKATA RAVI KUMAR VANTARAM (CFO) · VENKATA RAVI KUMAR VANTARAM (Whole-time director) · CHAVA SATYANARAYANA (Whole-time director) · VENKATA LAKSHMANA RAO CHUNDURU (Whole-time director) · SOUMYA CHAVA (Whole-time director) · KRISHNA CHAITANYA CHAVA (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 20+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence87/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment93/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 2,062.31 cr already registered.
- Compliance record supports lending.
Investor view90/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events26 Jun 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
21 Mar 2025
Charge created
Others - 200.00 cr
07 Nov 2024
Charge satisfied
Axis Bank Limited
31 Oct 2024
Charge satisfied
Hdfc Bank Limited
21 Oct 2024
Charge satisfied
Others
29 Aug 2024
Charge created
Others - 258.00 cr
25 Jul 2024
Director appointed
RAMESH SUBRAHMANIAN (Director)
10 Jul 2024
Director ceased
SOUMYA CHAVA
Director ceased
SEKAR KARNAM
Director ceased
KRISHNA CHAITANYA CHAVA
20 May 2024
Director appointed
VENKATESWAR REDDY GOGIREDDY (Nodal Officer)
25 Apr 2024
Director appointed
SOUMYA CHAVA (Whole-time director)
Director appointed
SEKAR KARNAM (Director)
Director appointed
KRISHNA CHAITANYA CHAVA (Whole-time director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
16 active director(s) / partner(s); review board churn before relying on management continuity.
5 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 23 security allotment(s) - amounts available in the full report.
9 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Bbil | U24119KA2016PLC093936 | Bengaluru, Karnataka, India |
| Himadri | L27106WB1987PLC042756 | Kolkata, West Bengal, India |
| Tatachemicals | L24239MH1939PLC002893 | Mumbai, Maharashtra, India |
| Atul | L99999GJ1975PLC002859 | Ahmedabad, Gujarat, India |
| Piramal Pharma | L24297MH2020PLC338592 | Mumbai, Maharashtra, India |
| Bayer India | L24210MH1958PLC011173 | Thane West, Maharashtra, India |
| Pcblltd | L23109WB1960PLC024602 | Kolkata, West Bengal, India |
| Alembic Pharmaceuticals | L24230GJ2010PLC061123 | Vadodara, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lauruslabs before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lauruslabs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Lauruslabs - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Lauruslabs pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Lauruslabs - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lauruslabs an active company?
Lauruslabs has MCA status “Active” with a compliance score of 86/100 (Low Risk).
Is Lauruslabs financially healthy?
Lauruslabs has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Lauruslabs?
Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lauruslabs?
Promoters hold a minority stake - exact percentages are in the full report. 16 active director(s) are on record.
Does Lauruslabs have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 34 earlier charge(s) stand satisfied.
Is Lauruslabs up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).
Is it risky to lend to Lauruslabs?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
